ePoster

All ePoster presentations will be available to view anytime throughout the Meeting in an Online Library

Title:

A Comparison of Outcome Measures used for Visual Improvement in Two Retinal Prostheses: Argus II and Alpha-AMS

Poster Details

First Author: M. Johnson UK

Co Author(s):    E. Ansari                    

Abstract Details

Purpose:

The first retinal prosthesis was implanted in 2002. Since then, new devices have been developed, two of which have been approved for use in humans, the Argus II and the Alpha-AMS. In studies of patients with retinal prosthetic devices, a variety of outcome measures are used. This literature review aims to compare what measurements are used to quantify visual acuity and assess visual function in this group of low vision patients.

Setting:

Systematic Literature Review

Methods:

A systematic literature search using MEDLINE, Cochrane Library, and MeSH terms was conducted using a comprehensive search strategy to identify studies related to the Argus II or the Alpha AMD devices that included information on the visual acuity or visual functioning of patients, and how this was conducted. Inclusion criteria involved peer-reviewed publications within the last 5 years, in the English language.

Results:

Testing methods utilised to assess visual function varied between devices. The Argus II used a grating acuity, localisation, and letter recognition tests. The Alpha-AMS utilized the Basic Light and Motion Test, the Freiburg Visual Acuity and Contrast Test, and a grating acuity test. Tests of functional vision were more varied, but involved object recognition, and assessment of simulated activities of daily living.

Conclusions:

Quantifying vision improvement for low vision patients remains difficult. Presently there is significant heterogeneity in the testing used and no uniform measurement across these devices exists. Whilst results to restore vision have been reported positively, knowledge regarding visual processing, and therefore the future of these devices is lacking.

Financial Disclosure:

None